Non-Cochrane · prognostic · PM41338120
BRAF p.V600E Mutation in Mixed Odontogenic Tumors and Its Clinical Correlation: A Systematic Review and Meta-Analysis.
Chantarangsu Soranun, Phattarataratip Ekarat, Lam-Ubol Aroonwan · International dental journal · 2026 · PubMed · doi:10.1016/j.identj.2025.109302
Findings
72 findings
| Population | ||||
|---|---|---|---|---|
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibroma (AF) | AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) | Male sex | OR 0.54 [0.24, 1.23] GRADE not reported 4 studies · 100 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibroma (AF) | AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) | Mandibular location (vs maxilla) | OR 1.99 [0.78, 5.12] GRADE not reported 4 studies · 99 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibroma (AF) | AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) | Age at diagnosis (years) | MD 1.49 [-3.89, 6.88] GRADE not reported 3 studies · 99 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibroma (AF) | AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) | BRAF p.V600E mutation prevalence | OR 1.87 [0.78, 4.46] GRADE not reported 3 studies · 100 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibroma (AF) | AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) | Lesion size (cm) | MD -0.44 [-1.78, 0.91] GRADE not reported 2 studies · 64 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibroma (AF) | AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) | Recurrence | OR 11.32 [0.57, 226.72] GRADE not reported 1 study · 41 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibroma (AF) | Odontoma (OD) | Lesion size (cm) | MD 2.20 [1.09, 3.31] GRADE not reported 1 study · 50 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibroma (AF) | Odontoma (OD) | Age at diagnosis (years) | MD -2.75 [-6.21, 0.72] GRADE not reported 2 studies · 69 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibroma (AF) | Odontoma (OD) | Recurrence | OR 11.32 [0.57, 226.72] GRADE not reported 1 study · 38 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibroma (AF) | Odontoma (OD) | Male sex | OR 1.00 [0.33, 3.04] GRADE not reported 2 studies · 70 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibroma (AF) | Odontoma (OD) | Mandibular location (vs maxilla) | OR 2.85 [0.84, 9.60] GRADE not reported 2 studies · 69 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibroma (AF) | Odontoma (OD) | BRAF p.V600E mutation prevalence | OR 26.33 [2.58, 268.78] GRADE not reported 2 studies · 70 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibrosarcoma (AFS) | Ameloblastic fibroma (AF) | BRAF p.V600E mutation prevalence | OR 2.73 [0.35, 21.52] GRADE not reported 2 studies · 60 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibrosarcoma (AFS) | Ameloblastic fibroma (AF) | Mandibular location (vs maxilla) | OR 1.68 [0.16, 17.27] GRADE not reported 2 studies · 58 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibrosarcoma (AFS) | Ameloblastic fibroma (AF) | Lesion size (cm) | MD -0.50 [-1.89, 0.89] GRADE not reported 1 study · 34 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibrosarcoma (AFS) | Ameloblastic fibroma (AF) | Age at diagnosis (years) | MD 7.76 [-1.79, 17.30] GRADE not reported 2 studies · 59 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibrosarcoma (AFS) | Ameloblastic fibroma (AF) | Male sex | OR 1.47 [0.19, 11.56] GRADE not reported 2 studies · 60 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibrosarcoma (AFS) | Ameloblastic fibroma (AF) | Recurrence | OR 17.22 [0.69, 427.87] GRADE not reported 1 study · 27 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) | Odontoma (OD) | Age at diagnosis (years) | MD -0.93 [-4.33, 2.48] GRADE not reported 2 studies · 78 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) | Odontoma (OD) | Male sex | OR 1.62 [0.52, 4.99] GRADE not reported 2 studies · 78 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) | Odontoma (OD) | Mandibular location (vs maxilla) | OR 1.31 [0.24, 7.06] GRADE not reported 2 studies · 78 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) | Odontoma (OD) | Lesion size (cm) | MD 3.20 [1.97, 4.43] GRADE not reported 1 study · 52 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) | Odontoma (OD) | BRAF p.V600E mutation prevalence | OR 19.15 [2.24, 163.52] GRADE not reported 2 studies · 78 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibrosarcoma (AFS) | AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) | Lesion size (cm) | MD -1.50 [-2.98, -0.02] GRADE not reported 1 study · 36 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibrosarcoma (AFS) | AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) | Age at diagnosis (years) | MD 8.51 [1.81, 15.22] GRADE not reported 2 studies · 68 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibrosarcoma (AFS) | AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) | BRAF p.V600E mutation prevalence | OR 3.57 [0.46, 27.99] GRADE not reported 2 studies · 68 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibrosarcoma (AFS) | AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) | Recurrence | OR 195.00 [3.12, 12187.23] GRADE not reported 1 study · 30 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibrosarcoma (AFS) | AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) | Mandibular location (vs maxilla) | OR 3.80 [0.40, 36.12] GRADE not reported 2 studies · 67 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibrosarcoma (AFS) | AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) | Male sex | OR 0.71 [0.05, 9.51] GRADE not reported 2 studies · 68 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibrosarcoma (AFS) | Odontoma (OD) | Recurrence | OR 195.00 [3.12, 12187.23] GRADE not reported 1 study · 27 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibrosarcoma (AFS) | Odontoma (OD) | Age at diagnosis (years) | MD 6.71 [-0.07, 13.49] GRADE not reported 2 studies · 38 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibrosarcoma (AFS) | Odontoma (OD) | Male sex | OR 1.59 [0.18, 14.02] GRADE not reported 2 studies · 38 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibrosarcoma (AFS) | Odontoma (OD) | Mandibular location (vs maxilla) | OR 4.19 [0.40, 43.66] GRADE not reported 2 studies · 37 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibrosarcoma (AFS) | Odontoma (OD) | Lesion size (cm) | MD 1.70 [0.61, 2.79] GRADE not reported 1 study · 22 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Ameloblastic fibrosarcoma (AFS) | Odontoma (OD) | BRAF p.V600E mutation prevalence | OR 49.71 [3.39, 729.32] GRADE not reported 2 studies · 38 participants |
| Patients with mixed odontogenic tumors with BRAF p.V600E testing | Odontoma (OD) | BRAF wild-type AFO/AFD/DO | Age at diagnosis (years) | MD 4.44 [-4.93, 13.80] GRADE not reported 2 studies · 48 participants |
| Patients with Ameloblastic fibroma (AF) with BRAF p.V600E testing | BRAF p.V600E-mutated lesion | BRAF p.V600E wild-type lesion | Female vs male sex (odds of BRAF+) | OR 5.76 [1.19, 27.88] GRADE not reported 3 studies · 46 participants |
| Patients with Ameloblastic fibroma (AF) with BRAF p.V600E testing | BRAF p.V600E-mutated lesion | BRAF p.V600E wild-type lesion | Lesion size (cm): BRAF+ vs BRAF- | MD 0.16 [-1.95, 2.26] GRADE not reported 2 studies · 31 participants |
| Patients with Ameloblastic fibroma (AF) with BRAF p.V600E testing | BRAF p.V600E-mutated lesion | BRAF p.V600E wild-type lesion | Age (years): BRAF+ vs BRAF- | MD 2.57 [-4.18, 9.32] GRADE not reported 3 studies · 45 participants |
| Patients with ameloblastic fibroma (AF) tested for BRAF p.V600E | BRAF p.V600E-mutated AF | BRAF wild-type AF | Recurrence (no evidence of disease vs recurrence) Not specified | OR 2.75 [0.28, 26.61] GRADE not reported 1 study · 19 participants |
| Patients with Ameloblastic fibroma (AF) with BRAF p.V600E testing | BRAF p.V600E-mutated lesion | BRAF p.V600E wild-type lesion | Maxilla vs mandible (odds of BRAF+) | OR 1.52 [0.32, 7.25] GRADE not reported 3 studies · 45 participants |
| Patients with AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) with BRAF p.V600E testing | BRAF p.V600E-mutated lesion | BRAF p.V600E wild-type lesion | Lesion size (cm): BRAF+ vs BRAF- | MD -0.40 [-2.17, 1.36] GRADE not reported 2 studies · 33 participants |
| Patients with AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) with BRAF p.V600E testing | BRAF p.V600E-mutated lesion | BRAF p.V600E wild-type lesion | Female vs male sex (odds of BRAF+) | OR 1.93 [0.30, 12.23] GRADE not reported 3 studies · 54 participants |
| Patients with AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) with BRAF p.V600E testing | BRAF p.V600E-mutated lesion | BRAF p.V600E wild-type lesion | Maxilla vs mandible (odds of BRAF+) | OR 0.51 [0.15, 1.66] GRADE not reported 3 studies · 54 participants |
| Patients with AFO/AFD/DO (ameloblastic fibro-odontoma, fibro-dentinoma, developing odontoma) with BRAF p.V600E testing | BRAF p.V600E-mutated lesion | BRAF p.V600E wild-type lesion | Age (years): BRAF+ vs BRAF- | MD 2.99 [-3.27, 9.24] GRADE not reported 3 studies · 54 participants |
| Patients with Ameloblastic fibrosarcoma (AFS) with BRAF p.V600E testing | BRAF p.V600E-mutated lesion | BRAF p.V600E wild-type lesion | Female vs male sex (odds of BRAF+) | OR 3.43 [0.24, 48.10] GRADE not reported 2 studies · 14 participants |
| Patients with Ameloblastic fibrosarcoma (AFS) with BRAF p.V600E testing | BRAF p.V600E-mutated lesion | BRAF p.V600E wild-type lesion | Age (years): BRAF+ vs BRAF- | MD -2.60 [-19.66, 14.46] GRADE not reported 1 study · 14 participants |
| Patients with Ameloblastic fibrosarcoma (AFS) with BRAF p.V600E testing | BRAF p.V600E-mutated lesion | BRAF p.V600E wild-type lesion | Maxilla vs mandible (odds of BRAF+) | OR 2.14 [0.06, 77.54] GRADE not reported 1 study · 13 participants |
| Patients with ameloblastic fibroma (AF) tested for BRAF p.V600E | ameloblastic fibroma (AF) | None (single-group descriptive summary pooled across included case reports and series) | Recurrence rate (%) Not specified | Recurrence (%) 21.1 GRADE not reported 19 participants |
| Patients with ameloblastic fibroma (AF) tested for BRAF p.V600E | ameloblastic fibroma (AF) | None (single-group descriptive summary pooled across included case reports and series) | Prevalence of BRAF p.V600E mutation (% of cases positive) Not specified | Prevalence (%) 67.4 GRADE not reported 46 participants |
| Patients with ameloblastic fibroma (AF) tested for BRAF p.V600E | ameloblastic fibroma (AF) | None (single-group descriptive summary pooled across included case reports and series) | Lesion size (cm) Not specified | Mean (SD) 4.12 GRADE not reported Studies not reported |
| Patients with ameloblastic fibroma (AF) tested for BRAF p.V600E | ameloblastic fibroma (AF) | None (single-group descriptive summary pooled across included case reports and series) | Recurrence rate (%) Not specified · Treatment: Enucleation, curettage or osteotomy | Recurrence (%) 23.1 GRADE not reported 13 participants |
| Patients with ameloblastic fibroma (AF) tested for BRAF p.V600E | ameloblastic fibroma (AF) | None (single-group descriptive summary pooled across included case reports and series) | Age at diagnosis (years) Not specified | Mean (SD) 16.91 GRADE not reported Studies not reported |
| Patients with ameloblastic fibroma (AF) tested for BRAF p.V600E | ameloblastic fibroma (AF) | None (single-group descriptive summary pooled across included case reports and series) | Recurrence rate (%) Not specified · Treatment: Resection | Recurrence (%) 16.7 GRADE not reported 6 participants |
| Patients with ameloblastic fibro-odontoma, ameloblastic fibro-dentinoma or developing odontoma (AFO/AFD/DO) tested for BRAF p.V600E | ameloblastic fibro-odontoma, ameloblastic fibro-dentinoma or developing odontoma (AFO/AFD/DO) | None (single-group descriptive summary pooled across included case reports and series) | Age at diagnosis (years) Not specified | Mean (SD) 13.46 GRADE not reported Studies not reported |
| Patients with ameloblastic fibro-odontoma, ameloblastic fibro-dentinoma or developing odontoma (AFO/AFD/DO) tested for BRAF p.V600E | ameloblastic fibro-odontoma, ameloblastic fibro-dentinoma or developing odontoma (AFO/AFD/DO) | None (single-group descriptive summary pooled across included case reports and series) | Recurrence rate (%) Not specified | Recurrence (%) 4.5 GRADE not reported 22 participants |
| Patients with ameloblastic fibro-odontoma, ameloblastic fibro-dentinoma or developing odontoma (AFO/AFD/DO) tested for BRAF p.V600E | ameloblastic fibro-odontoma, ameloblastic fibro-dentinoma or developing odontoma (AFO/AFD/DO) | None (single-group descriptive summary pooled across included case reports and series) | Recurrence rate (%) Not specified · Treatment: Enucleation, curettage or osteotomy | Recurrence (%) 5.9 GRADE not reported 17 participants |
| Patients with ameloblastic fibro-odontoma, ameloblastic fibro-dentinoma or developing odontoma (AFO/AFD/DO) tested for BRAF p.V600E | ameloblastic fibro-odontoma, ameloblastic fibro-dentinoma or developing odontoma (AFO/AFD/DO) | None (single-group descriptive summary pooled across included case reports and series) | Lesion size (cm) Not specified | Mean (cm) 4.48 GRADE not reported Studies not reported |
| Patients with ameloblastic fibro-odontoma, ameloblastic fibro-dentinoma or developing odontoma (AFO/AFD/DO) tested for BRAF p.V600E | ameloblastic fibro-odontoma, ameloblastic fibro-dentinoma or developing odontoma (AFO/AFD/DO) | None (single-group descriptive summary pooled across included case reports and series) | Prevalence of BRAF p.V600E mutation (% of cases positive) Not specified | Prevalence (%) 55.6 GRADE not reported 54 participants |
| Patients with ameloblastic fibro-odontoma, ameloblastic fibro-dentinoma or developing odontoma (AFO/AFD/DO) tested for BRAF p.V600E | ameloblastic fibro-odontoma, ameloblastic fibro-dentinoma or developing odontoma (AFO/AFD/DO) | None (single-group descriptive summary pooled across included case reports and series) | Recurrence rate (%) Not specified · Treatment: Resection | Recurrence (%) 0.0 GRADE not reported 5 participants |
| Patients with odontoma (OD) tested for BRAF p.V600E | odontoma (OD) | None (single-group descriptive summary pooled across included case reports and series) | Recurrence rate (%) Not specified | Recurrence (%) 0.0 GRADE not reported 19 participants |
| Patients with odontoma (OD) tested for BRAF p.V600E | odontoma (OD) | None (single-group descriptive summary pooled across included case reports and series) | Age at diagnosis (years) Not specified | Mean (SD) 17.71 GRADE not reported Studies not reported |
| Patients with odontoma (OD) tested for BRAF p.V600E | odontoma (OD) | None (single-group descriptive summary pooled across included case reports and series) | Lesion size (cm) Not specified | Mean (SD) 1.78 GRADE not reported Studies not reported |
| Patients with odontoma (OD) tested for BRAF p.V600E | odontoma (OD) | None (single-group descriptive summary pooled across included case reports and series) | Prevalence of BRAF p.V600E mutation (% of cases positive) Not specified | Prevalence (%) 0.0 GRADE not reported 24 participants |
| Patients with odontoma (OD) tested for BRAF p.V600E | odontoma (OD) | None (single-group descriptive summary pooled across included case reports and series) | Recurrence rate (%) Not specified · Treatment: Enucleation, curettage or osteotomy | Recurrence (%) 0.0 GRADE not reported 19 participants |
| Patients with ameloblastic fibrosarcoma (AFS) tested for BRAF p.V600E | ameloblastic fibrosarcoma (AFS) | None (single-group descriptive summary pooled across included case reports and series) | Age at diagnosis (years) Not specified | Mean (SD) 25.93 GRADE not reported Studies not reported |
| Patients with ameloblastic fibrosarcoma (AFS) tested for BRAF p.V600E | ameloblastic fibrosarcoma (AFS) | None (single-group descriptive summary pooled across included case reports and series) | Lesion size (cm) Not specified | Mean (SD) 4.5 GRADE not reported Studies not reported |
| Patients with ameloblastic fibrosarcoma (AFS) tested for BRAF p.V600E | ameloblastic fibrosarcoma (AFS) | None (single-group descriptive summary pooled across included case reports and series) | Recurrence rate (%) Not specified | Recurrence (%) 37.5 GRADE not reported 8 participants |
| Patients with ameloblastic fibrosarcoma (AFS) tested for BRAF p.V600E | ameloblastic fibrosarcoma (AFS) | None (single-group descriptive summary pooled across included case reports and series) | Recurrence rate (%) Not specified · Treatment: Enucleation, curettage or osteotomy | Recurrence (%) 100.0 GRADE not reported 1 participants |
| Patients with ameloblastic fibrosarcoma (AFS) tested for BRAF p.V600E | ameloblastic fibrosarcoma (AFS) | None (single-group descriptive summary pooled across included case reports and series) | Prevalence of BRAF p.V600E mutation (% of cases positive) Not specified | Prevalence (%) 71.4 GRADE not reported 14 participants |
| Patients with ameloblastic fibrosarcoma (AFS) tested for BRAF p.V600E | ameloblastic fibrosarcoma (AFS) | None (single-group descriptive summary pooled across included case reports and series) | Recurrence rate (%) Not specified · Treatment: Resection | Recurrence (%) 20.0 GRADE not reported 5 participants |
| Patients with ameloblastic fibrosarcoma (AFS) tested for BRAF p.V600E | ameloblastic fibrosarcoma (AFS) | None (single-group descriptive summary pooled across included case reports and series) | Recurrence rate (%) Not specified · Treatment: Resection plus chemotherapy | Recurrence (%) 50.0 GRADE not reported 2 participants |
Included primary studies 17
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Agaimy 2020 Ameloblastic fibrosarcoma: clinicopathological and molecular analysis of seven cases highlighting frequent <i>BRAF</i> and occasional… DOI:10.1111/his.14053 | 2020 | this review only | not stated | not extracted yet |
| Agaimy 2020 Ameloblastic fibrosarcoma: clinicopathological and molecular analysis of seven cases highlighting frequent BRAF and occasional NRAS… PMID:31899815 | 2020 | this review only | not stated | not extracted yet |
| Barakeh 2023 Ameloblastic Fibrosarcoma of the Jaw: Case Report, Genetic Profiling, and Literature Review DOI:10.1159/000532014 | 2023 | this review only | not stated | not extracted yet |
| Barakeh 2023 Ameloblastic Fibrosarcoma of the Jaw: Case Report, Genetic Profiling, and Literature Review. PMID:37942402 | 2023 | this review only | not stated | not extracted yet |
| Coura 2020 Targeted Next-Generation Sequencing and Allele-Specific Quantitative PCR of Laser Capture Microdissected Samples Uncover Molecular… DOI:10.1016/j.jmoldx.2020.08.005 | 2020 | this review only | not stated | not extracted yet |
| Coura 2020 Targeted Next-Generation Sequencing and Allele-Specific Quantitative PCR of Laser Capture Microdissected Samples Uncover Molecular… PMID:32966885 | 2020 | this review only | not stated | not extracted yet |
| de Gracia Hahn 2025 Ameloblastic fibroma and BRAF V600E immunohistochemistry staining pattern: case report and review of a rare entity DOI:10.1016/j.ijom.2025.02.010 | 2025 | this review only | not stated | not extracted yet |
| de Gracia Hahn 2025 Ameloblastic fibroma and BRAF V600E immunohistochemistry staining pattern: case report and review of a rare entity. PMID:40102082 | 2025 | this review only | not stated | not extracted yet |
| Guo 2024 Are Ameloblastic Fibroma-related Lesions True Tumors? DOI:10.1097/pas.0000000000002319 | 2024 | this review only | not stated | not extracted yet |
| Guo 2024 Are Ameloblastic Fibroma-related Lesions True Tumors?: Evidence Through CNA and BRAF Mutation Analysis. PMID:39450987 | 2024 | this review only | not stated | not extracted yet |
| Niki-Yonekawa 2024 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Roza 2025 New Insights into Ameloblastic Fibromas, Fibrodentinomas, and Fibro-Odontomas: Findings from an International Multicenter Study DOI:10.1007/s12105-025-01792-0 | 2025 | this review only | not stated | not extracted yet |
| Roza 2025 New Insights into Ameloblastic Fibromas, Fibrodentinomas, and Fibro-Odontomas: Findings from an International Multicenter Study. PMID:40338415 | 2025 | this review only | not stated | not extracted yet |
| Ver Berne 2025 Rethinking Ameloblastic Fibroma and Fibro-odontoma: A Serie of 6 Cases and Reclassification Proposal DOI:10.1007/s12105-025-01818-7 | 2025 | this review only | not stated | not extracted yet |
| Ver Berne 2025 Rethinking Ameloblastic Fibroma and Fibro-odontoma: A Serie of 6 Cases and Reclassification Proposal. PMID:40560304 | 2025 | this review only | not stated | not extracted yet |
| Zhukov 2019 Potentially Curative Targeted Therapy for Undifferentiated High-Grade Sarcoma Developing After Malignant Transformation of a <i>BRAF</i>… DOI:10.1200/po.19.00282 | 2019 | this review only | not stated | not extracted yet |
| Zhukov 2019 Potentially Curative Targeted Therapy for Undifferentiated High-Grade Sarcoma Developing After Malignant Transformation of a BRAF… PMID:35100728 | 2019 | this review only | not stated | not extracted yet |
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Patients diagnosed with ameloblastic fibroma (AF), developing odontoma (DO), ameloblastic fibro-odontoma (AFO), ameloblastic fibro-dentinoma (AFD), odontoma (OD), odontogenic sarcoma (OS) or ameloblastic fibrosarcoma (AFS), with BRAF p.V600E mutation detection results | 138 patients: 46 AF, 54 AFO/AFD/DO, 24 OD, 14 AFS (n=138) |
| Intervention | BRAF p.V600E mutation status (exposure) and tumor type | BRAF p.V600E mutation detected by genetic methods and/or immunohistochemistry |
| Comparison | Comparison between tumor groups (AF, AFO/AFD/DO, OD, AFS) and between BRAF p.V600E-mutated and wild-type lesions | Pairwise comparisons among AF, AFO/AFD/DO, OD and AFS; BRAF-mutated vs wild-type within AF, AFO/AFD/DO and AFS |
| Outcomes | Prevalence of BRAF p.V600E mutation; age, sex, lesion location, lesion size, recurrence | BRAF p.V600E prevalence, age, mandibular location, male sex, lesion size, recurrence |
| Study designs | Observational studies, cross-sectional, cohort, case-control, case series and case reports published from 1990 | 9 studies: 5 case series and 4 case reports (n=9) |
| Timing | Not specified | Not specified |